To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.
November 16 – 17, 2015 | Heidelberg, Germany | Innovations in Oncology Workshop
November 16th and 17th 2015, Xentech will attend to Innovations in Oncology Workshop in Heidelberg. The event bring together scientists and physicians from academics to industry to discuss the latest findings in cancer science and medicine, including our scientists! Come to see us and discover our latest innovations about PDX used in cancer […]
Contract Research Organization
XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....